Benralizumab for <i>PDGFRA</i> -Negative Hypereosinophilic Syndrome

2019211 citationsJournal Articlebronze Open Access

Authors

Fei Li Kuang · Jiangsu Institute of Parasitic Diseases

Fanny Legrand · Jiangsu Institute of Parasitic Diseases

Michelle Makiya · Jiangsu Institute of Parasitic Diseases

JeanAnne Ware · Jiangsu Institute of Parasitic Diseases

Lauren Wetzler · Jiangsu Institute of Parasitic Diseases

Thomas Brown · Jiangsu Institute of Parasitic Diseases

Tamika Magee

Abstract

In this small phase 2 trial, patients with <i>PDGFRA</i>-negative hypereosinophilic syndrome who received benralizumab for 12 weeks had lower absolute eosinophil counts than those who received placebo. During the open-label phase, clinical and hematologic responses were sustained for 48 weeks in 74% of the patients. Adverse events did not limit treatment. (Funded by the National Institute of Allergy and Infectious Diseases; ClinicalTrials.gov numbers, NCT00001406 and NCT02130882.).

Topics & Keywords

Eosinophilic Disorders and Syndromes Eosinophilic Esophagitis Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 380, Issue 14, pp. 1336-1346

DOI: 10.1056/nejmoa1812185

Field-Weighted Citation Impact: 22.68